Finch Therapeutics to Participate in Upcoming June Investor Conferences
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from...